(MedPage Today) — The FDA approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in adults with complement 3 glomerulopathy (C3G), the agency announced Thursday.
“C3G is a debilitating disease often affecting young people…
Source link : https://www.medpagetoday.com/nephrology/generalnephrology/114779
Author :
Publish date : 2025-03-21 19:50:00
Copyright for syndicated content belongs to the linked Source.
